Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on LinkedIn:
“Such a treat to present on ‘Tumor‑Agnostic Drug Development: Where Are We and Where Are We Headed‘ at the STOP Cancer Symposium.
The audience energy, panel debate, and especially the Q&A made it unforgettable.
Yes! We need 50 more tumor‑agnostic drugs in the next 50 years.
Our patients can’t wait.”
Other articles featuring Vivek Subbiah on OncoDaily.
